Increased dosages of quetiapine increase somnolence
Clinical literature and pharmacological reviews consistently identify sedation and somnolence as well-established, dose-dependent adverse effects of quetiapine.
The retrieved papers consistently report that sedation and somnolence are frequent adverse events associated with quetiapine administration, aligning with established pharmacological knowledge regarding its antihistaminic and adrenergic receptor blockade properties at higher doses. None of the provided papers refute the claim.
Glen I. Spielmans, Margit I. Berman, Eftihia Linardatos, Nicholas Rosenlicht, Angela Perry, Alexander C. Tsai. Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. 2013. https://doi.org/10.1371/journal.pmed.1001403
Identifies sedation and somnolence as known adverse effects associated with quetiapine treatment.
See more details
Nizar El-Khalili. Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. 2012. https://doi.org/10.2147/ndt.s14369
Notes that somnolence and sedation are among the most common adverse events linked to quetiapine use across its formulations.
Berrio A, Chrones L, Abler V, Hauser RA. Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.. 2025. https://doi.org/10.1016/j.prdoa.2025.100342
Indicates that quetiapine and other atypical antipsychotics carry an increased, dose-dependent risk of sedation and sleep-related adverse events like drowsiness.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt